Impact of Anxiety and Depression on Survival in Hematologic Malignancies

Overview

This systematic review and meta-analysis evaluated the association of anxiety and depression with survival outcomes in patients with hematologic malignancies. Findings indicate that both depression and anxiety are prevalent in this population and are independently linked to reduced overall survival and event-free survival.

Background

Hematologic malignancies, including leukemia, lymphoma, and myeloma, represent a significant global cancer burden with varying survival rates depending on subtype. Psychological disorders such as anxiety and depression are common among these patients due to disease burden, treatment side effects, and psychosocial stressors. These psychiatric conditions have been shown to negatively affect treatment adherence, immune function, and quality of life, potentially worsening prognosis. However, evidence regarding their impact on survival in hematologic malignancies has been inconsistent, necessitating a comprehensive meta-analysis.

Data Highlights

The meta-analysis incorporated studies assessing depression and anxiety using validated clinical or self-report measures and examined their relationship with survival outcomes such as overall survival (OS) and event-free survival (EFS) in hematologic malignancy patients. Prevalence rates of anxiety and depression ranged from 20% to 30% in this population, with a 6.7-fold increased risk of depression compared to the general population. Survival data demonstrated that depressive symptoms were associated with worse OS and EFS, particularly in acute myeloid leukemia (AML) patients. Anxiety showed a less consistent but still negative impact on survival.

Key Findings

• Depression and anxiety are highly prevalent in patients with hematologic malignancies, affecting approximately 20-30% of patients.
• Patients with hematologic malignancies have a 6.7-fold increased risk of developing depression compared to the general population.
• Depression is independently associated with reduced overall survival (OS) and event-free survival (EFS), especially in acute myeloid leukemia (AML).
• Anxiety is also linked to poorer OS, though its impact is less consistent across studies.
• Psychological disorders may impair treatment adherence and immune function, contributing to worse clinical outcomes.
• There is a need for routine screening and management of anxiety and depression in hematologic malignancy patients to improve prognosis.

Clinical Implications

Clinicians should be vigilant in screening for anxiety and depression in patients with hematologic malignancies, given their high prevalence and negative impact on survival. Integrating psychological assessment and appropriate interventions into standard oncologic care may enhance treatment adherence and improve overall outcomes. Addressing these mental health conditions is essential for holistic patient management.

Conclusion

Anxiety and depression significantly compromise survival outcomes in patients with hematologic malignancies. Targeted strategies to identify and treat these psychiatric disorders are critical to optimizing prognosis and quality of life in this vulnerable population.

References

1. Zhang et al. 2024 -- Prevalence of Anxiety and Depression in Cancer Patients
2. SEER Database 2020 -- Survival Statistics in Hematologic Malignancies
3. WHO Classification 2022 -- Hematolymphoid Neoplasms
4. PRISMA Guidelines 2024 -- Systematic Review Methodology